Pharmacological perspectives in sarcopenia: A potential role for renin-angiotensin system blockers?

Clinical Cases in Mineral and Bone Metabolism

Volumn 12, Issue 2, 2015, Pages 135-138

  Sartiani, Laura ^a   Spinelli, Valentina ^a   Laurino, Annunziatina ^a   Blescia, Sabrina ^a   Raimondi, Laura ^a   Cerbai, Elisabetta ^a   Mugelli, Alessandro ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Angiotensin; Angiotensin receptors blockers; Angiotensin converting enzyme inhibitors; Sarcopenia; Skeletal muscle

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

DRUG EFFECT; HUMAN; MUSCLE ATROPHY; MUSCLE REGENERATION; MUSCLE STRENGTH; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SARCOPENIA; SKELETAL MUSCLE;

EID: 84945575134     PISSN: 17248914     EISSN: 19713266     Source Type: Journal    
DOI: 10.11138/ccmbm/2015.12.2.135     Document Type: Review

References (24)

1. Morley JE, Anker SD, von Haehling S. Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology-update 2014. J Cachexia Sarcopenia Muscle. 2014;5:253.
2. Hida T, Harada A, Imagama S, Ishiguro N. Managing Sarcopenia and Its Related-Fractures to Improve Quality of Life in Geriatric Populations. Aging Dis. 2014;5(4):226-237.
3. Komajda M, Hanon O, Aupetit JF, Benetos A, Berrut G, Emeriau JP, Friocourt P, Galinier M, De Groote P, Jondeau G, Jourdain P, Forette F. Management of heart failure in the elderly: recommendations from the French Society of Cardiology (SFC) and the French Society of Gerontology and Geriatrics (SFGG). J Nutr Health Aging. 2006;10:434-44.
4. Rolland Y, Czerwinski S, Van Kan GA, Morley JE, Cesari M, Onder G, Baumgartner WR, Pillard F, Boirie Y, Chumlea WMC, Vellas B. Sar-copenia: its assessment, etiology, pathogenesis, consequences and future perspectives. J Nutr Health Aging. 2008;12(7):433-450.
5. Rinaldi F, Perlingeiro RC. Stem cells for skeletal muscle regeneration: therapeutic potential and roadblocks. Transl Res. 2014;163:409-17.
6. Wakabayashi H, Sakuma K. Comprehensive approach to sarcopenia treatment. Curr Clin Pharmacol. 2014;9:171-8.
7. Shi Y, Lo CS, Padda R, Abdo S, Chenier I, Filep JG, Ingelfinger JR, Zhang SL, Chan JS. Ang 1-7 Prevents Systemic Hypertension, Attenuates Oxidative Stress and Tubulointerstitial Fibrosis, and Normalizes Renal Angiotensin-Converting Enzyme 2 and Mas Receptor Expression in Diabetic Mice. Clin Sci (Lond). 2014 Dec 12. [Epub ahead of print].
8. Guang C, Phillips RD, Jiang B, Milani F. Three key proteases-an-giotensin-I-converting enzyme (ACE), ACE2 and renin-within and beyond the renin-angiotensin system. Arch Cardiovasc Dis. 2012;105(6-7):373-85.
9. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev. 2006;86(3):747-803.
10. Yoshida T, Galvez S, Tiwari S, Rezk BM, Semprun-Prieto L, Higashi Y, Sukhanov S, Yablonka-Reuveni Z, Delafontaine P. Angiotensin II inhibits satellite cell proliferation and prevents skeletal muscle regeneration. J Biol Chem. 2013;288(33): 23823-32.
11. Yoshida T, Huq TS, Delafontaine P. Angiotensin type 2 receptor signaling in satellite cells potentiates skeletal muscle regeneration. J Biol Chem. 2014;289(38):26239-48.
12. Anker SD, Negassa A, Coats AJS, Afzal R, Poole-Wilson PA, Cohn JN, et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin converting-enzyme inhibitors: an observational study. Lancet. 2003;361:1077-1083.
13. Puthucheary Z, Skipworth JR, Rawal J, Loosemore M, Van Someren K, Montgomery. The ACE Gene and Human Performance: 12 Years On. Sports Med. 2011;41(6):433-448.
14. Onder G, Penninx BW, Balkrishnan R, Fried LP, Chaves PH, Williamson J, Carter C, Di Bari M, Guralnik JM, Pahor M. Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study. Lancet. 2002;359(9310):926-30.
15. Pozos-López T, Navarrete-Reyes AP, Ávila-Funes JA. Is frailty associated with cardiovascular drug use? J Am Geriatr Soc. 2011;59:1977-9.
16. Vescovo G1, Dalla Libera L, Serafini F, Leprotti C, Facchin L, Volterrani M, Ceconi C, Ambrosio GB. Improved exercise tolerance after losartan and enalapril in heart failure: correlation with changes in skeletal muscle myosin heavy chain composition. Circulation. 1998;98(17):1742-9.
17. Dalla Libera L, Ravara B, Angelini A, Rossini K, Sandri M, Thiene G, et al. Beneficial effects on skeletal muscle of the angiotensin II type 1 receptor blocker irbesartan in experimental heart failure. Circulation. 2001;103:2195-2200.
18. Burks TN, Andres-Mateos E, Marx R, Mejias R, Van Erp C, Simmers JL, Walston JD, Ward CW, Cohn D. Losartan restores skeletal muscle remodeling and protects against disuse atrophy in sarcopenia. Sci Transl Med. 2011;3(82): 82ra37.
19. Cohn RD, van Erp C, Habashi JP, Soleimani AA, Klein EC, Lisi MT, Gamradt M, ap Rhys CM, Holm TM, Loeys BL, Ramirez F, Judge DP, Ward CW, Dietz HC. Angiotensin II type 1 receptor blockade attenuates TGF-β-induced failure of muscle regeneration in multiple myopathic states. Nat Med. 2007;13:204-210.
20. Sumukadas D, Witham MD, Struthers AD, et al. Effect of perindopril on physical function in elderly people with functional impairment: a randomized controlled trial. CMAJ. 2007;177:867-74.
21. Johnston AP, Baker J, Bellamy LM, McKay BR, De Lisio M, Parise G. Regulation of muscle satellite cell activation and chemotaxis by an-giotensin II. PLoS One. 2010;5(12):e15212.
22. Meneses C, Morales MG, Abrigo J, Simon F, Brandan E, Cabello-Ver-rugio C. The angiotensin-(1-7)/Mas axis reduces myonuclear apoptosis during recovery from angiotensin II-induced skeletal muscle atrophy in mice. Pflugers Arch. 2014 Oct 9. [Epub ahead of print].
23. Cisternas F, Morales MG, Meneses C, Simon F, Brandan E, Abrigo J, Vazquez Y, Cabello-Verrugio C. Angiotensin-(1-7) decreases skeletal muscle atrophy induced by angiotensin II through a Mas receptor-dependent mechanism. Clin Sci (Lond). 2015;128(5):307-19.
24. Verdonk K, Danser AH, van Esch JH. Angiotensin II type 2 receptor agonists: where should they be applied? Expert Opin Investig Drugs. 2012;21(4):501-13.